The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Open accessAbstract
Cell-based therapies are emerging as effective agents against cancer and other diseases. As autonomous “living drugs,” these therapies lack precise control. Chimeric antigen receptor (CAR) T cells effectively target hematologic malignancies but can proliferate rapidly and cause toxicity. We developed ON and OFF switches for CAR T cells using the clinically approved drug lenalidomide, which mediates the proteasomal degradation of several target proteins by inducing interactions between the CRL4 CRBN E3 ubiquitin ligase and a C2H2 zinc finger degron motif. We performed a systematic screen to identify “super-degron” tags with enhanced sensitivity to lenalidomide-induced degradation and used these degradable tags to generate OFF-switch degradable CARs. To create an ON switch, we engineered a lenalidomide-inducible dimerization system and developed split CARs that required both lenalidomide and target antigen for activation. Subtherapeutic lenalidomide concentrations controlled the effector functions of ON- and OFF-switch CAR T cells. In vivo, ON-switch split CARs demonstrated lenalidomide-dependent antitumor activity, and OFF-switch degradable CARs were depleted by drug treatment to limit inflammatory cytokine production while retaining antitumor efficacy. Together, the data showed that these lenalidomide-gated switches are rapid, reversible, and clinically suitable systems to control transgene function in diverse gene- and cell-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Self-citationTargeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 1×
“In future applications, if necessary, effects of degron or dimerization domains on receptor function could be mitigated by altering gene dosage or per-molecule signaling strength along established lines ( 34 , 36 , 42 , 43 ).”
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Self-citationAn auxin-based degron system for the rapid depletion of proteins in nonplant cells
Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T., & Kanemaki, M. (2009) · Nature Methods · doi:10.1038/nmeth.1401 · Cited by 1,663 · cited 1×
“Multiple systems now exist to regulate protein degradation, including the incorporation of destabilization domains ( 9 ), or sequences triggering auxin-induced degradation ( 10 ), ligand-induced degradation ( 11 ), and small molecule–assisted shutoff ( 12 ), or dTags ( 13 ).”
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156 · cited 1×
“Although demonstrating remarkable efficacy culminating in clinical approvals for the treatment of B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma (22), CARs pose a risk from toxic T cell hyperactivation (23).”
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
The dTAG system for immediate and target-specific protein degradation
Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118
Banaszynski, L. A., Chen, L.-C., Maynard-Smith, L. A., Ooi, A. G. L., & Wandless, T. J. (2006) · Cell · doi:10.1016/j.cell.2006.07.025 · Cited by 902
Therapeutic T cell engineering
Sadelain, M., Rivière, I., & Riddell, S. (2017) · Nature · doi:10.1038/nature22395 · Cited by 879
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Self-citationRichardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Design and Selection of Novel Cys2His2 Zinc Finger Proteins
Pabo, C. O., Peisach, E., & Grant, R. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.313 · Cited by 715
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Cho, J. H., Collins, J. J., & Wong, W. W. (2018) · Cell · doi:10.1016/j.cell.2018.03.038 · Cited by 682
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620
Tuning the Antigen Density Requirement for CAR T-cell Activity
Majzner, R. G., Rietberg, S. P., Sotillo, E., Dong, R., Vachharajani, V. T., Labanieh, L., Myklebust, J. H., Kadapakkam, M., Weber, E. W., Tousley, A. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0945 · Cited by 573
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
Feucht, J., Sun, J., Eyquem, J., Ho, Y.-J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., & Sadelain, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0290-5 · Cited by 547
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537 · cited 10×
“…to mediate thalidomide analog–dependent binding to CRBN ( 18 ) and encoded this library into a lentiviral degradation reporter vector wherein the zinc finger is tagged to enhanced green fluorescent protein (eGFP) and followed by an internal ribosome entry site (IRES)– mCherry element (18) .”
InfluentialSelf-citationHudecek, M., Sommermeyer, D., Kosasih, P. L., Silva-Benedict, A., Liu, L., Rader, C., Jensen, M. C., & Riddell, S. R. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0127 · Cited by 532
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5907 · Cited by 531
Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531
Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 523
Donovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife · doi:10.7554/elife.38430 · Cited by 509 · cited 1×
“Multiple zinc fingers in human proteins are individually capable of mediating drug-dependent degradation at different efficiencies (18, 20).”
Self-citationThe Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 446
Self-citationA safe and potent anti-CD19 CAR T cell therapy
Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., Guo, X., Liu, H., Ding, N., Zhang, T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0421-7 · Cited by 441
Cell-Based Therapeutics: The Next Pillar of Medicine
Fischbach, M. A., Bluestone, J. A., & Lim, W. A. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005568 · Cited by 419
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0129-x · Cited by 338
Schade, A. E., Schieven, G. L., Townsend, R., Jankowska, A. M., Susulic, V., Zhang, R., Szpurka, H., & Maciejewski, J. P. (2008) · Blood · doi:10.1182/blood-2007-04-084814 · Cited by 296
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Frey, N. V., Shaw, P. A., Hexner, E. O., Pequignot, E., Gill, S., Luger, S. M., Mangan, J. K., Loren, A. W., Perl, A. E., Maude, S. L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01892 · Cited by 271
Chiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D. A., Reardon, D. A., Wen, P., Stopa, B. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5680 · Cited by 263
Diaconu, I., Ballard, B., Zhang, M., Chen, Y., West, J., Dotti, G., & Savoldo, B. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.011 · Cited by 250
Pharmacologic control of CAR-T cell function using dasatinib
Weber, E. W., Lynn, R. C., Sotillo, E., Lattin, J., Xu, P., & Mackall, C. L. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028720 · Cited by 239
Yeku, O. O., & Brentjens, R. J. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150291 · Cited by 237
Tunable and reversible drug control of protein production via a self-excising degron
Chung, H. K., Jacobs, C. L., Huo, Y., Yang, J., Krumm, S. A., Plemper, R. K., Tsien, R. Y., & Lin, M. Z. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1869 · Cited by 233
The novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213
Self-citationSmall-molecule displacement of a cryptic degron causes conditional protein degradation
Bonger, K. M., Chen, L.-C., Liu, C. W., & Wandless, T. J. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.598 · Cited by 206
Prosser, M. E., Brown, C. E., Shami, A. F., Forman, S. J., & Jensen, M. C. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.03.023 · Cited by 184
Wang, X., Walter, M., Urak, R., Weng, L., Huynh, C., Lim, L., Wong, C. W., Chang, W.-C., Thomas, S. H., Sanchez, J. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0344 · Cited by 182
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S. (2017) · Nature Communications · doi:10.1038/ncomms15398 · Cited by 176
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Scarfò, I., Ormhøj, M., Frigault, M. J., Castaño, A. P., Lorrey, S., Bouffard, A. A., Scoyk, A. V., Rodig, S. J., Shay, A. J., Aster, J. C., et al. (2018) · Blood · doi:10.1182/blood-2018-04-842708 · Cited by 145
Self-citationHamann, J., Fiebig, H., & Strauss, M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.11.4920 · Cited by 141
Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib
Weichsel, R., Dix, C., Wooldridge, L., Clement, M., Fenton-May, A. E., Sewell, A. K., Zezula, J., Greiner, E., Emma Gostick, D., Price, D. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4393 · Cited by 137
The Pharmacology of T Cell Therapies
Milone, M. C., & Bhoj, V. G. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.010 · Cited by 108
Works, M. G., Soni, N., Hauskins, C., Sierra, C., Baturevych, A., Jones, J. C., Curtis, W., Carlson, P., Johnstone, T. G., Kugler, D. G., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1146 · Cited by 90
Leung, W., Gay, J. W., Martin, U., Garrett, T. E., Horton, H. M., Certo, M. T., Blazar, B. R., Morgan, R. A., Gregory, P. D., Jarjour, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124430 · Cited by 88
Clinical pharmacokinetics and pharmacodynamics of lenalidomide
Chen, N., Zhou, S., & Palmisano, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0432-1 · Cited by 86
Chemical Inducers of Targeted Protein Degradation
Raina, K., & Crews, C. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.078105 · Cited by 70
Sperling, A. S., Burgess, M. W., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Slabicki, M. M., Sellar, R. S., Fink, E. C., Miller, P. G., et al. (2019) · Blood · doi:10.1182/blood.2019000789 · Cited by 68
Self-citationKuramitsu, S., Ohno, M., Ohka, F., Shiina, S., Yamamichi, A., Kato, A., Tanahashi, K., Motomura, K., Kondo, G., Kurimoto, M., et al. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.47 · Cited by 64
Bedoya, F., Frigault, M. J., & Maus, M. V. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.011 · Cited by 44
Self-citationSynthetic Biology: Immunotherapy by Design
Brenner, J., Cho, J. H., Wong, N. M. L., & Wong, W. W. (2018) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-121147 · Cited by 29
Weber, E. W., Lynn, R. C., Parker, K. R., Anbunathan, H., Lattin, J., Sotillo, E., Good, Z., Malipatlolla, M., Xu, P., Vandris, P., et al. (2020) · doi:10.1101/2020.01.26.920496 · Cited by 18 · cited 1×
“Using dasatinib or a destabilization domain, transient rest from CAR signaling protects against T cell exhaustion ( 50 ); future work may establish whether lenalidomide ON-or OFF-switch control enhances the phenotype and function of exhaustion-prone CARs.”
Cited by
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Daniel, B., Klysz, D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 607
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Flugel, C. L., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou-el-Enein, M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00704-3 · Cited by 554
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 396
Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02148-6 · Cited by 310
Metadata
- Authors
- Jan, M., Scarfò, I., Larson, R. C., Walker, A., Schmidts, A., Guirguis, A. A., Gasser, J. A., Słabicki, M., Bouffard, A. A., Castano, A. P., Kann, M. C., Cabral, M. L., Tepper, A., Grinshpun, D. E., Sperling, A. S., Kyung, T., Sievers, Q. L., Birnbaum, M. E., Maus, M. V., & Ebert, B. L.
- Venue
- Science Translational Medicine
- Published
- 2021-01-06
- Volume
- 13
- Issue
- 575
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3120439501
- Cited by
- 267
- References
- 57
- FWCI
- 14.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.